<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02944188</url>
  </required_header>
  <id_info>
    <org_study_id>ERAS-02</org_study_id>
    <secondary_id>82345432</secondary_id>
    <nct_id>NCT02944188</nct_id>
  </id_info>
  <brief_title>Laparoscopic Versus Open Right Hemicolectomy Within ERAS in Right-sided Colon Cancer</brief_title>
  <official_title>Laparoscopic Versus Open Right Hemicolectomy Within Enhanced Recovery After Surgery(ERAS) Programs in the Treatment of Right-sided Colon Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xu jianmin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators have compared the clinical outcomes of the laparoscopic and
      open right hemicolectomy within enhanced recovery after surgery (ERAS) programs in the
      treatment of right-sided colon cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>3 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operative complications</measure>
    <time_frame>1 month post operatively</time_frame>
    <description>intra, and postoperative complications related to operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operative mortality</measure>
    <time_frame>30 days post operatively</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>operative time</measure>
    <time_frame>Day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>rate of conversion to open surgery</measure>
    <time_frame>Day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>estimated blood loss</measure>
    <time_frame>Day 1</time_frame>
    <description>Blood loss will be measured according to the suction and the weight of wet gauze, and then minus the irrigation.</description>
  </other_outcome>
  <other_outcome>
    <measure>number of retrieved lymph nodes</measure>
    <time_frame>1 week post operatively</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>postoperative hospital stay</measure>
    <time_frame>30 days post operatively</time_frame>
    <description>The postoperative hospital stay is defined as the number of date from the first day after operation to discharge.</description>
  </other_outcome>
  <other_outcome>
    <measure>self reported bladder function</measure>
    <time_frame>at postoperative 3, 6 and 12 months</time_frame>
    <description>This section is assessed using a self-rating scale &quot;International prostate symptom score&quot; (IPSS).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>LRH plus ERAS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients undergo Laparoscopic right hemicolectomy plus ERAS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ORH plus ERAS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients undergo open right hemicolectomy plus ERAS</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic right hemicolectomy plus ERAS</intervention_name>
    <description>patients treated with Laparoscopic right hemicolectomy plus enhanced recovery after surgery (ERAS) programs</description>
    <arm_group_label>LRH plus ERAS</arm_group_label>
    <other_name>LRH ERAS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Open right hemicolectomy plus ERAS</intervention_name>
    <description>patients treated Open right hemicolectomy plus enhanced recovery after surgery (ERAS) programs</description>
    <arm_group_label>ORH plus ERAS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 and ≤ 75 years;

          2. Primary tumor has undergone histologically confirmed colon adenocarcinoma; Colon
             cancer was defined by the presence of the inferior pole of the tumor above the
             peritoneal reflection (at least 15 cm from the anal margin).

          3. Together with clinical or radiological evidence of Stage(T1-2,N0, M0) Stage II (T3-4,
             N0, M0) or Stage III (T1-4, N1-2, M0) disease (according to the 2007 revision of the
             International Union Against Cancer TNM staging system)

          4. Performance status (ECOG) 0~1

          5. Adequate hematological function: Neutrophils≥1.5 x109/l and platelet count≥100 x109/l;
             Hb ≥9g/dl (within 1 week prior to randomization)

          6. Adequate hepatic and renal function: Serum bilirubin≤1.5 x upper limit of normal
             (ULN), alkaline phosphatase ≤5x ULN, and serum transaminase (either AST or ALT) ≤ 5 x
             ULN(within 1 week prior to randomization);

          7. Written informed consent for participation in the trial.

        Exclusion Criteria:

          1. Other previous malignancy within 5 years, with exception of a history of a previous
             basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix

          2. Pregnancy (absence confirmed by serum/urine β-HCG) or breast-feeding

          3. Known drug abuse/ alcohol abuse

          4. Legal incapacity or limited legal capacity

          5. Pre-existing peripheral neuropathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Jiang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianmin Xu, MD</last_name>
    <phone>86-18917982975</phone>
    <email>xujmin@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pingping Xu, MD</last_name>
      <phone>86-21-18917982975</phone>
    </contact>
    <investigator>
      <last_name>jianmin xu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2015</study_first_submitted>
  <study_first_submitted_qc>October 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2016</study_first_posted>
  <last_update_submitted>October 23, 2016</last_update_submitted>
  <last_update_submitted_qc>October 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xu jianmin</investigator_full_name>
    <investigator_title>Deputy director of the colorectal cancer center</investigator_title>
  </responsible_party>
  <keyword>enhanced recovery after surgery</keyword>
  <keyword>right hemicolectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

